Skip to main content
Caplight Logo









Novaliq

Novaliq

Private
HeidelbergHealthcare & Life Scienceshttps://www.novaliq.com/

Last Round

VC Round

Oct 11, 2018

Total Funding Raised

$17.8M

Company Overview

Novaliq is a biopharmaceutical company that develops and commercializes ocular therapeutics based on its proprietary EyeSol® water-free technology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

ophthalmologydrug deliverydry eye diseasebiopharmaceuticalocular therapeuticswater-free technologyeye dropspreservative-freedrug licensingocular surface diseasebiotechpharma licensingdrug formulationophthalmic solutions

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Novaliq Comparables

Compare Novaliq with similar companies based on industry and business-model similarity.

Novaliq comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bausch + Lomb Corporation
84%
Harrow, Inc.
79%
Aldeyra Therapeutics
76%

Novaliq Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 11, 2018
VC RoundApr 11, 2013
VC RoundMay 4, 2012
VC RoundJul 27, 2011

Key People

Founding team and executive leadership

Oliver Schlueter

Managing Director, CFO

Executive Team

Novaliq Investors

Notable investors and investment history

Novaliq investors
InvestorRounds
dievini Hopp BioTech holdingVC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2025

    EyeSol technology drug approved in China in 2025.

  • Jan 1, 2024

    EyeSol technology drug received regulatory approval in Europe in 2024.

Novaliq Filings

Explore SEC and related filing metadata, where available.

Novaliq filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Novaliq's valuation, stock price, and market status.

Is Novaliq a public or private company?

Novaliq is a private company.

What is the current stock price of Novaliq?

Novaliq is a private company with no public stock price. No recent secondary market data is available.

How much is Novaliq worth (valuation)?

Valuation information for Novaliq is not publicly available.

Can I buy Novaliq stock?

Novaliq shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Novaliq's last funding round?

Novaliq's most recent funding round was Series C on October 11, 2018.

Who are the main investors in Novaliq?

Investor information for Novaliq is not publicly disclosed.

Will Novaliq IPO soon?

No public IPO plans have been announced for Novaliq.

How can I track Novaliq secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Novaliq's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHeidelberg
Employee Range24
Year Founded2007
Last FundingOct 11, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?